18781-42-5

Basic information

• Product Name: methyl 2-methyl-1-benzothiophene-6-carboxylate
• Synonyms: Benzo(b)thiophene-6-carboxylic acid, 2-methyl-, methyl ester; Benzo[b]thiophene-6-carboxylic acid, 2-methyl-, methyl ester
• CAS NO: 18781-42-5
• Molecular Formula: C₁₁H₁₀O₂S
• Molecular Weight: 206.2609
• Mol File: 18781-42-5.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 322.3°C at 760 mmHg
• Flash Point: 148.7°C
• Density: 1.233g/cm³
• Vapor Pressure: 0.000281mmHg at 25°C
• Refractive Index: 1.624
• CAS DataBase Reference: methyl 2-methyl-1-benzothiophene-6-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 2-methyl-1-benzothiophene-6-carboxylate(18781-42-5)
• EPA Substance Registry System: methyl 2-methyl-1-benzothiophene-6-carboxylate(18781-42-5)

Safety Data

• Hazardous Substances Data: 18781-42-5(Hazardous Substances Data)

Upstream product

• 17347-32-9 6-bromobenzothiophene 
• 67-56-1 methanol 
• 912332-92-4 6-bromo-2-methylbenzo[b]thiophene 
• 201230-82-2 carbon monoxide 

Relevant articles and documents

De Novo Synthesis of Benzannelated Heterocycles

Benzannelated heterocycles such as indoles and indazoles are prominent structural motifs found in natural products, pharmaceuticals and agrochemicals. For their synthesis, chemists traditionally either functionalize commercially available heterocycles or resort to transformations that make use of benzene-derived building blocks. Here, we report a powerful cascade reaction that enables the de novo construction of variously substituted indoles, indazoles, benzofurans and benzothiophenes from readily available bicyclo[3.1.0]hexan-2-ones. The transformation can be conducted under mild, non-anhydrous conditions. For the synthesis of indoles, mechanistic studies revealed that the electrocyclic ring-opening of the bicyclic ring-system and aromatization precedes the 3,3-sigmatropic rearrangement.

IMIDAZOPYRIDAZINE COMPOUNDS

The present invention relates to novel substituted imidazo[1,2-b] pyridazine compounds of Formula (I) pharmaceutical compositions thereof, and the use such compounds as corticotropin releasing factor 1 (CRF1) receptor antagonists in the treatment of psychiatric disorders and neurological diseases.